Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro Carpeno, J., . . . Brahmer, J. (2021). Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. J Clin Oncol.
Citação norma ChicagoBorghaei, Hossein, et al. "Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer." J Clin Oncol 2021.
Citação norma MLABorghaei, Hossein, et al. "Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer." J Clin Oncol 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.